Elderberry chewing gum for thinking and mouth bacteria in older adults
Tests elderberry gum on thinking and mouth bacteria in seniors.
Key facts
- Who runs it
- Burdur Mehmet Akif Ersoy University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Elderberry Functional Gum and Cognitive & Oral Health in Older Adults
- Status
- Not yet recruiting
- People taking part
- 34 people, planned
- Started
- 1 Nov 2025
- Planned end
- 1 Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Elderberry Anthocyanin Chewing Gum
- Placebo Chewing Gum
- Record updated
- 8 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for older adults with mildly reduced memory and thinking. It tests an elderberry chewing gum against a gum without the active ingredient.
- Age
- The criteria say 60 and over; the record's minimum age is 65 Years.
- Sex
- All sexes can join.
- Disease stage
- Mildly reduced thinking ability, with a MoCA test score of 20-25. Other long-term diseases must be stable, for example high blood pressure or controlled diabetes.
- Earlier treatment
- No probiotics, prebiotics or antibiotics in the last three months. No antiseptic mouthwashes that could strongly affect mouth bacteria. Regular medicines are allowed.
- Biomarker or test result
- MoCA score 20-25.
Main reasons for not taking part
- Moderate to severe dementia (MoCA < 20)
- Active infection or a whole-body inflammatory disease
- Jaw joint problems that make chewing gum hard
- Smokers, or people without good teeth (fewer than 20 natural teeth, unless a working denture lets them chew without problems)
- Known allergy to elderberry or its parts
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Individuals aged 60 and over
- Individuals with mildly reduced cognitive function using the MoCA test (MoCA score: 20-25)
- Those with stable systemic diseases (e.g. HT, controlled DM)
- Those with adequate dental health (≥20 natural teeth or no chewing problems with functional prosthesis)
- Non-smokers and those who use regular medication and do not use antibiotics or antiseptic mouthwashes that could seriously affect the oral microbiota
- Individuals who are willing to participate in the study and can give written consent
Who cannot take part
- Moderate to severe dementia (MoCA < 20)
- Presence of active infection or systemic inflammatory disease
- Temporomandibular joint disorders affecting gum chewing function
- Known allergy to elderberry or its components
- Use of probiotics, prebiotics, or antibiotics within the last three months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Globally, the aging population is increasing rapidly, leading to a dramatic rise in the prevalence of Alzheimer's disease and other types of dementia. Neurodegenerative disorders are characterized by pathological hallmarks such as β-amyloid (Aβ) plaque accumulation, tau protein aggregation, synaptic loss, and widespread neuroinflammation. These processes impair key cognitive domains including attention, memory, executive function, and orientation, hindering independent daily functioning.
Read full original descriptionShow less
Beyond cognitive decline, neurodegenerative diseases are associated with a marked deterioration in oromotor functions, such as chewing and swallowing. Mastication plays a critical role not only in digestion but also in neuro-sensory stimulation. Trigeminal nerve signaling activated by chewing enhances neurotransmitter release, boosts neurotrophic factor production (e.g., BDNF), and facilitates Aβ clearance, thereby supporting synaptic plasticity and reducing inflammation. Neuroimaging studies have shown that a higher number of functional occlusal pairs is associated with increased gray and white matter volume in regions affected early in Alzheimer's disease.
Systematic reviews have identified poor mastication and tooth loss as risk factors for cognitive decline and dementia. Mechanistically, loss of afferent input from the oral cavity-due to tooth loss, reduced chewing force, prosthetic use, or muscle atrophy-leads to reduced brain stimulation, diminished neurotrophic support, and impaired cerebral blood flow. Thus, geriatric-friendly chewing gum formulations with low elasticity and ease of chewing have been recommended.
Chewing gum is a promising vehicle for functional compounds due to its potential for transmucosal absorption and cognitive stimulation. Randomized controlled trials have shown that both active and inactive gums improve attention and reduce error rates in cognitive tasks, highlighting the beneficial effects of mastication.
Another emerging target for cognitive enhancement is the oral microbiota, a complex ecosystem of over 700 bacterial species. Dysbiosis in this ecosystem has been linked to neurological outcomes via inflammatory and neurotoxic pathways. Certain pathogens, such as Porphyromonas gingivalis, have been detected in the brains of Alzheimer's patients. Moreover, metagenomic studies have shown that reduced salivary microbial diversity correlates with poorer cognitive performance, even in young adults.
Elderberry (Sambucus nigra L.) is rich in anthocyanins (e.g., cyanidin-3-glucoside, cyanidin-3-sambubioside) with strong antioxidant and anti-inflammatory properties. Literature shows that polyphenols can be absorbed via buccal and sublingual mucosa, bypassing first-pass metabolism and providing faster systemic effects. However, the impact of anthocyanin-enriched chewing gum on oral microbiota and cognitive function has not yet been systematically investigated.
This study aims to develop and evaluate a geriatric-friendly functional chewing gum enriched with standardized elderberry anthocyanins. The intervention targets dual mechanisms-neurophysiological and microbial-to support cognitive health and balance oral microbiota in older adults.
The 2 groups in the trial
- Elderberry Chewing Gum GroupTreatment being tested
Participants receive chewing gum containing standardized elderberry anthocyanins twice daily for 6 weeks
Treatment: Elderberry Anthocyanin Chewing Gum
- Placebo Arm TitlePlacebo, for comparison
Participants receive anthocyanin-free chewing gum matched in appearance and taste, twice daily for 6 weeks
Treatment: Placebo Chewing Gum
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Effects of Elderberry-Based Anthocyanin-Enriched Functional Chewing Gum on Cognitive Functions and Oral Microbiota in Older Adults: A Double-Blind, Randomized Controlled Trial
- Plain-language title
- Elderberry chewing gum for thinking and mouth bacteria in older adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 8 July 2025